Aiforia’s change negotiations concluded - measures aimed to enhance company's competitiveness and profitability

Aiforia Technologies Plc, Press release, November 18, 2025 at 11:00 a.m. EET

As part of broader financial adjustment measures, Aiforia Technologies announced on October 31, 2025, that it will start change negotiations. The objective of the financial adjustment measures is to improve the company's business competitiveness and profitability and to ensure the achievement of the company’s mid-term business targets.

The change negotiations initiated on November 5, 2025, in accordance with the Act on Co-operation within Undertakings, covered 43 people in Aiforia Technologies Plc's Finnish operations. At the start of the negotiations, the company assessed that the planned changes would lead to the termination of the employment of a maximum of 9 people in Aiforia’s Finnish operations.

As a result of the negotiations, the number of employees will be reduced by 8 people. In addition, Aiforia has initiated other measures to improve efficiency and to save costs. The personnel reductions, as well as the restructuring and streamlining of functions and tasks, are expected to deliver ongoing annual cost savings of approximately EUR 2.5 million, starting from the 2026 financial year. The measures will be implemented by the end of 2025.

“The measures are part of a strategic shift where the focus is moving to stronger product commercialization. With the change negotiations, we have taken an important step towards a more efficient and competitive organization that supports our growth and profitability in the long term,” says the company's CEO, Jukka Tapaninen.

Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/

Certified Adviser 
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

About Aiforia 

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient. 

Find out more at www.aiforia.com